BAVA Stock Overview
Develops, manufactures, and commercializes life-saving vaccines.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Bavarian Nordic A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | DKK 217.10 |
52 Week High | DKK 300.00 |
52 Week Low | DKK 125.55 |
Beta | 1.54 |
11 Month Change | -10.66% |
3 Month Change | 17.35% |
1 Year Change | 65.92% |
33 Year Change | -30.08% |
5 Year Change | 34.26% |
Change since IPO | -14.86% |
Recent News & Updates
Recent updates
Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher
Aug 26Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models
Aug 25Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly
Aug 09Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit
Jul 11Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts
May 12Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet
Apr 09Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Feb 26Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry
Jan 03Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate
Dec 10Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly
Nov 15Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Aug 17Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet
Apr 19Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?
Jan 03Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?
Sep 15Shareholder Returns
BAVA | DK Biotechs | DK Market | |
---|---|---|---|
7D | 2.9% | 0.3% | -0.9% |
1Y | 65.9% | 6.8% | 19.7% |
Return vs Industry: BAVA exceeded the Danish Biotechs industry which returned 9.5% over the past year.
Return vs Market: BAVA exceeded the Danish Market which returned 19.8% over the past year.
Price Volatility
BAVA volatility | |
---|---|
BAVA Average Weekly Movement | 8.9% |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 4.2% |
10% most volatile stocks in DK Market | 8.9% |
10% least volatile stocks in DK Market | 2.4% |
Stable Share Price: BAVA's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: BAVA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 1,381 | Paul Chaplin | www.bavarian-nordic.com |
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.
Bavarian Nordic A/S Fundamentals Summary
BAVA fundamental statistics | |
---|---|
Market cap | DKK 17.05b |
Earnings (TTM) | DKK 707.42m |
Revenue (TTM) | DKK 6.08b |
24.1x
P/E Ratio2.8x
P/S RatioIs BAVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BAVA income statement (TTM) | |
---|---|
Revenue | DKK 6.08b |
Cost of Revenue | DKK 2.06b |
Gross Profit | DKK 4.02b |
Other Expenses | DKK 3.31b |
Earnings | DKK 707.42m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 15, 2024
Earnings per share (EPS) | 9.01 |
Gross Margin | 66.08% |
Net Profit Margin | 11.63% |
Debt/Equity Ratio | 0.2% |
How did BAVA perform over the long term?
See historical performance and comparison